HUTCHMED (CHINA) LIMIT

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

16 May 2024 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

13 May 2024 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

13 May 2024 19:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

10 May 2024 08:45:09 By NetDania Notify

NetDania - New 12 months High: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

09 May 2024 08:45:13 By NetDania Notify

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

08 May 2024 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

26 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

05 Apr 2024 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

01 Apr 2024 23:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

27 Mar 2024 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

21 Mar 2024 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

28 Feb 2024 05:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

06 Feb 2024 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

02 Feb 2024 02:30:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Final Results

01 Feb 2024 02:30:00 By Nasdaq GlobeNewswire

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

29 Jan 2024 22:53:49 By Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

10 Jan 2024 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

12 Dec 2023 22:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

12 Dec 2023 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

30 Nov 2023 18:00:00 By Nasdaq GlobeNewswire